SCHEMBL13705290

SCHEMBL13705290

O=C(OCc1ccccc1)N1CCN[C@H](CCNc2ccc(-n3cccn3)cc2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 8/20 0.45
CYP2D6 P10635 4/20 0.45
CYP2C9 P11712 4/20 0.45
CXCR4 P61073 1/20 0.41
CYP3A4 P08684 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ENPP2 Q13822 1/20 0.37
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
USP30 Q70CQ3 1/20 0.37
CTSL P07711 1/20 0.36
CTSK P43235 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
DRD1 P21728 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4283259 0.86 HDAC4 (0.40) CXCR4HRH3
SCHEMBL13705274 0.86 GRIN2B (0.50) GRIN2BCYP2D6CYP2C9CXCR4CYP3A4
SCHEMBL8118175 0.83 GRIN2B (0.43) GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2
SCHEMBL13705285 0.82 GRIN2B (0.45) GRIN2BCYP2D6CYP2C9CXCR4CYP3A4
SCHEMBL13705286 0.81 P2RY1 (0.46) GRIN2BCYP2D6CYP2C9CXCR4SMN1; SMN2
SCHEMBL8116637 0.77 CCR3 (0.44) GRIN2BCYP2D6CYP2C9CXCR4CYP3A4
SCHEMBL29901356 0.75 SMN1; SMN2 (0.51) GRIN2BCYP2D6CYP2C9CXCR4SMN1; SMN2
SCHEMBL8112938 0.74 SMN1; SMN2 (0.50) GRIN2BCYP2D6CYP2C9CXCR4SMN1; SMN2
SCHEMBL29277609 0.74 SMN1; SMN2 (0.52) GRIN2BCYP2D6CYP2C9CXCR4SMN1; SMN2
SCHEMBL29277610 0.74 SMN1; SMN2 (0.52) GRIN2BCYP2D6CYP2C9CXCR4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT GRIN2B 3673/4885CYP2D6 173/4885CYP2C9 40/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT GRIN2B 3673/4885CYP2D6 173/4885CYP2C9 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.